• MeSH
• Osteoarthritis, Hip etiology   prevention & control   MeSH
• Biomechanical Phenomena MeSH
• Child MeSH
• Hip surgery   physiopathology   pathology   MeSH
• Humans MeSH
• Adolescent MeSH
• Osteotomy methods   statistics & numerical data   MeSH
• Child, Preschool MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Bone Diseases, Developmental surgery   complications   pathology   MeSH
• Check Tag
• Child MeSH
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Child, Preschool MeSH
• Female MeSH

The authors present the results of a medium-term study in which they investigated the therapeutic effect of the silicone elastomer TopiGel on developing hypertrophic scars in a group of patients after burn injuries classified as Ilb or deeper. The hitherto published results are vety encouraging. This medium-term study confirmed the hypothesis that TopiGel has a positive effect on the reduction, stabilization and normalization of hypertrophic scars. In 48 patients (96 %) out of a total of 50, stabilization of the scar occurred as well as its functional and cosmetic normalization, although the subjective view of the patients or parents (in tase of pediatric patients) differed in some instances. In two children (4 %) only a significant reduction of the scar occurred and not normalization, due to incorrect application of the gel by the parents, lack of adherence to basic hygienic principles or the recommended procedure of gel application. In tase of repeated complications, treatment was not pursued. In two patients (4 %)treatment was discontinued for a short time due to an allergic skin reaction subsequently, treatment was resumed until complete stabilization of the scar was achieved. The study rued out a positive therapeutic effect of the silicone sheet on the painfulness of a scar and old, mature hypertrophic scars.

• MeSH
• Child MeSH
• Adult MeSH
• Cicatrix, Hypertrophic pathology   therapy   MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Burns complications   MeSH
• Child, Preschool MeSH
• Silicone Elastomers standards   therapeutic use   MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Child, Preschool MeSH
• Female MeSH
• Publication type
• Evaluation Study MeSH

• MeSH
• Hypertension therapy   MeSH
• Blood Pressure MeSH
• Humans MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Female MeSH
• Geographicals
• Czech Republic MeSH

• MeSH
• Transplantation, Autologous methods   MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Nerve Transfer methods   statistics & numerical data   MeSH
• Peripheral Nerves transplantation   MeSH
• Arm Injuries surgery   complications   MeSH
• Peripheral Nerve Injuries MeSH
• Treatment Outcome classification   statistics & numerical data   MeSH
• Plastic Surgery Procedures MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH

V multicentrické observační studii hodnotící klinickou účinnost léčby Sulperazonem (cefoperazon +sulbaktam)bylo sledováno 203 nemocných se závažnými a nozokomiálními infekčními komplikacemi.Většina nemocných byla hospitalizována v intenzivní péči (79,8 %).Léčba byla hodnocena jako úspěšná v 80,3 %,s maximem úspěšnosti u abdominálních infekcí (91,9 %).Nejnižší úspěšnost léčby byla zjištěna u septických nemocných (72,5 %) a u nemocných s pneumoniemi (76,4 %).Nejčastěji byl Sulperazon podán v dávce 2 x 2 g i.v./24 hodin po dobu 10 dní (medián).Nežádoucí účinky (1,5 %)nebyly ani v jednom případě indikací k přerušení léčby.Umělá plicní ventilace,pneumonie,nesprávná počáteční volba antibiotika a vyšší počet jednotlivých druhů aplikovaných antibiotik byly identifikovány jako významné rizikové faktory pro selhání antibiotické léčby.Sulperazon je hodnocen jako velmi dobře tolerované antibiotikum s výborným klinickým efektem,především u abdominálních infekcí se zanedbatelnými nežádoucími účinky.

The multicenter observational clinical trial evaluating clinical efficacy of Sulperazon (cefoperazone with sulbactam)followed 203 patients with severe and nosocomial infectious complications.Majority of the patients were admitted to the intensive care unit (79.8%).The therapy was successful in 80.3%with maximum efficacy in abdominal infections (91.9%).The lowest treatment efficacy was noted in the patients with sepsis (72.5%)and bronchopneumonia (76.4%).The most frequent treatment regime was 2x2 g i.v.in 24 hours for 10 days (median).The adverse effects were not in any case indication for the interruption of the treatment.Ventilatory support,pneumonia,incorrect initial choice of antibiotic and higher number of given antibiotics were significant risk factors for the failure of antibiotic therapy.Sulperazon was assessed as well tolerated antibiotics with excellent clinical efficacy mainly in abdominal infections with negligible adverse effects.

• MeSH
• Cefoperazone therapeutic use   MeSH
• Child MeSH
• Adult MeSH
• Cross Infection etiology   drug therapy   physiopathology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Risk Factors MeSH
• Aged MeSH
• Sulbactam therapeutic use   MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Aged MeSH
• Publication type
• Multicenter Study MeSH

• MeSH
• CA-125 Antigen blood   MeSH
• Humans MeSH
• Ovarian Neoplasms drug therapy   blood   MeSH
• Paclitaxel therapeutic use   MeSH
• Predictive Value of Tests methods   statistics & numerical data   MeSH
• Thymidine Kinase blood   MeSH
• Tissue Polypeptide Antigen blood   MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Female MeSH
• Publication type
• Comparative Study MeSH

• MeSH
• Appetite Depressants pharmacology   classification   therapeutic use   MeSH
• Safety MeSH
• Weight Loss MeSH
• Humans MeSH
• Heart Valve Diseases epidemiology   etiology   MeSH
• Obesity drug therapy   MeSH
• Risk MeSH
• Treatment Outcome economics   statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Comparative Study MeSH

• MeSH
• Antigens, Viral blood   MeSH
• Antiviral Agents therapeutic use   MeSH
• Cytomegalovirus Infections epidemiology   immunology   blood   MeSH
• Child MeSH
• Adult MeSH
• Humans MeSH
• Predictive Value of Tests MeSH
• Organ Transplantation MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Humans MeSH

• MeSH
• Epidemiologic Studies methods   standards   statistics & numerical data   MeSH
• Data Interpretation, Statistical methods   MeSH
• Medical Oncology statistics & numerical data   MeSH
• Humans MeSH
• Neoplasms diagnosis   epidemiology   therapy   MeSH
• Survival MeSH
• Treatment Outcome standards   statistics & numerical data   MeSH
• Records MeSH
• Check Tag
• Humans MeSH

Autoři provedli epidemiologickou studii, jejíž výsledky hodnotily terapii revmatoidní artritidy jednotlivými chorobu modifikujícími léky (DMARDs) z hlediska účinnosti a toxicity. Jednalo se o retrospektivní, multicentrickou studii, kdy byla využita dokumentace z 15 ambulantních i lůžko- vých revmatologických zařízení na území České a Slovenské republiky. Na základě této dokumen- tace byl lékařem vyplněn dotazník pro počítačové zpracování. Celkem bylo zachyceno 1162 případů přerušení terapie DMARDs u 760 pacientů s RA. Přerušení terapie z důvodů nežádoucích účinků bylo nejčastěji zachyceno u terapie zlatem a u terapie metotrexátem (u obou kolem 60 % dokumen- tovaných případů přerušení terapie). Nejméně často byla pro nežádoucí účinky vysazována antima- larika (necelých 25 %). Z důvodů nedostatečné účinnosti byla naopak nejčastěji vysazována antima- larika (66 %), nejméně často byl pro neúčinnost vysazován cyklofosfamid (necelých 20 %). Průměrná délka léčby DMARDs dosáhla téměř 30 měsíců. Překvapivě nejdéle byl podáván cyklofosfamid (průměrná délka podávání dosáhla 39 měsíců), nejkratší dobu byl podáván cyklosporin (průměrně 9 měsíců). Délka léčby signifikantně korelovala s věkem nemocného v době zahájení léčby, poziti- vitou revmatoidního faktoru, extraartikulárními příznaky a vzděláním nemocného. Naopak nebylo zjištěno ovlivnění délky podávání DMARDs dalšími sledovanými faktory (pohlaví, sedimentace, současné podávání kortikoidů).

The authors performed an epidemiological study which evaluated treatment of rheumatoid arthritis by different disease modifying drugs (DMARDs) from the aspect of effectiveness and toxicity. It was a retrospective multicentre trial where the documentation of 15 rheumatological out- an in-patient departments in the Czech and Slovak Republic was used. Based on this documentation the physician completed a questionnaire which was processed by computer. A total of 1162 cases of discontinued DMARDs therapy in 760 patients with RA was recorded. Discontinuation of therapy on account of side effects was recorded most frequently in gold therapy and in treatment with methotrexate (in both some 60% of documented cases discontinued treatment). The least frequent discontinuation for side effects was found with antimalarial drugs (less than 25 %). On the other hand, due to the insufficient effectiveness, the antimalarials were discontinued most frequently (66 %), whereas cyclophosphamide discontinuation was observed in the least number of cases (less than 20 %). The mean period of DMARDs therapy was almost 30 months. It is surprising that cyclophosphamide was administered for the longest period (mean 39 months). Cyclosporin was administered for the shortest period (mean 9 months). The period of treatment correlated significantly with the patient’s age at the time when treatment was started, with the positivity of the rheumatoid factor, extraarticular symptoms and the patient’s education. Conversely no relationship was found between the period of DMARDs administration and other factors such as sex, sedimentation rate, concurrent corticoid administration.

• MeSH
• Antirheumatic Agents therapeutic use   MeSH
• Adult MeSH
• Drug Therapy methods   statistics & numerical data   MeSH
• Research Support as Topic MeSH
• Middle Aged MeSH
• Humans MeSH
• Retrospective Studies MeSH
• Arthritis, Rheumatoid drug therapy   blood   pathology   MeSH
• Treatment Outcome statistics & numerical data   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Multicenter Study MeSH